| Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinson's disease patients. An ambulatory polysomnographic study. | |
| | |
MedLine Citation:
|
PMID: 18500498 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To investigate the sleep-wake cycle and the effects of cabergoline monotherapy in a homogenous group of de novo Parkinson's Disease (PD) patients without confounding comorbid factors. DESIGN AND PARTICIPANTS: Twelve de novo patients affected by idiopathic PD underwent two ambulatory polysomnographic (APSG)monitoring sessions. The first was performed at baseline, and the second recording one-month after stable treatment with cabergoline monotherapy. Subjective daytime sleepiness was evaluated by means of the Epworth Sleepiness Scale.Data obtained in PD patients at baseline were compared with those obtained in 12 age- and sex-matched healthy subjects. RESULTS: Diurnal sleep parameters did not show significant differences between controls and PD patients at baseline. In PD patients, no significant changes in diurnal sleep were observed between baseline and cabergoline treatment. Regarding nocturnal sleep, patients at baseline showed a significantly lower sleep efficiency and a significantly higher Wakefulness After Sleep Onset than controls. With respect to baseline, a significant increase in REM latency and a significant reduction in REM sleep were observed during cabergoline treatment. CONCLUSIONS: In the early stage of PD, the neurodegenerative process does not seem to be directly responsible for daytime somnolence, but it may be directly involved in the alteration of nocturnal sleep. Cabergoline monotherapy does not affect daytime sleep propensity and, despite clinical improvement, it may have negative effects on REM sleep. |
| | |
Authors:
|
Fabio Placidi; Francesca Izzi; Andrea Romigi; Paolo Stanzione; Maria Grazia Marciani; Livia Brusa; Francesca Sperli; Salvatore Galati; Patrizio Pasqualetti; Mariangela Pierantozzi |
Related Documents
:
|
7169198 - Correlations of some physical variables with rem sleep and slow wave sleep in man. 1557448 - Effect of burn wound bacterial colonization on sleep and respiratory pattern. 6744058 - Reversal of rapid eye movement sleep without atonia by chloramphenicol. 20971658 - Nonrem sleep mentation in chronically-treated persons with schizophrenia. 924738 - Intracapsular aspiration. 3014398 - Neonatal monosodium glutamate dosing alters the sleep-wake cycle of the mature rat. |
Publication Detail:
|
Type: Clinical Trial; Journal Article Date: 2008-06-02 |
Journal Detail:
|
Title: Journal of neurology Volume: 255 ISSN: 0340-5354 ISO Abbreviation: J. Neurol. Publication Date: 2008 Jul |
Date Detail:
|
Created Date: 2008-08-20 Completed Date: 2008-12-12 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0423161 Medline TA: J Neurol Country: Germany |
Other Details:
|
Languages: eng Pagination: 1032-7 Citation Subset: IM |
Affiliation:
|
Neurology Clinic, Dept. of Neuroscience, University of Rome,Tor Vergata Policlinico Tor Vergata, Servizio di Neurofisiopatologia, Centro di Medicina del Sonno, V.le Oxford 81, 00133 Rome, Italy. fbplacidi@libero.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antiparkinson Agents / therapeutic use* Case-Control Studies Ergolines / therapeutic use* Female Humans Male Middle Aged Outpatients Parkinson Disease / drug therapy*, physiopathology* Polysomnography / methods Severity of Illness Index Sleep / drug effects* Wakefulness / drug effects* |
| Chemical | |
Reg. No./Substance:
|
0/Antiparkinson Agents; 0/Ergolines; 81409-90-7/cabergoline |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Clinical features and associated syndromes of mal de debarquement.
Next Document: Rehabilitation in primary and metastatic brain tumours: impact of functional outcomes on survival.